Company: AVCRF
Filing Date: 2025-06-16
Form Type: 20-F
Source: 0001641172-25-015266
Chunk: 82

Company: Avricore Health Inc.
Filing Date: 2025-06-16
Form: 20-F
Item: Item 19
Chunk 82
---
 Company.                                                             
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────

Related
party transactions not otherwise described in the consolidated financial statements are shown below. The remuneration of the Company’s
directors and other members of key management, who have the authority and responsibility for planning, directing and controlling the
activities of the Company directly or indirectly, consist of the following:

SCHEDULE OF RELATED PARTY TRANSACTIONS

  Type                       2024           2023         2022  
  of transaction                                               
                                $              $            $  
 ───────────────────────────────────────────────────────────────
  Consulting              216,000        216,000      168,000  
  Management              216,000        216,000      168,000  
  Professional            128,400        128,400      124,200  
  Share-based             433,848        495,348      151,088  
  Related                 994,248      1,055,748      611,288  

At
December 31, 2024, there were no nil

Avricore
Health Inc.

Notes
to the Consolidated Financial Statements

For
the years ended December 31, 2024, 2023 and 2022

(Expressed
in Canadian Dollars)

  13.      CAPITAL      
           DISCLOSURES  
 ────────────────────────

The
Company includes Common shares, Options reserve and Warrants reserve in the definition of capital net of share issue costs. The Company’s
objective when managing capital is to maintain sufficient cash resources to support its day-to-day operations. The availability of capital
is solely through the issuance of the Company’s common shares. The Company intends to issue additional equity at such time when
funds are needed and the market conditions become favorable to the Company. There are no assurances that funds will be made available
to the Company when required. The Company makes every effort to safeguard its capital and minimize its dilution to its shareholders.

The
Company is not subject to any externally imposed capital requirements. There were no changes in the Company’s approach to capital
management during the year ended December 31, 2024.

  14.      SEGMENTED    
           INFORMATION  
 ────────────────────────

At
December 31, 2024 and 2023, the Company has only one segment, being the HealthTab